EC Number   |
Inhibitors |
Structure |
|---|
    1.14.19.17 | (Z)-4-((5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)amino)-N-hydroxybenzimidamide |
completely inhibits Des1 activity at 0.01 mM but shows little activity at 0.001 mM |
   |
| 1.14.19.17 | 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole |
SKi, a SK1/SK2 inhibitor |
|
| 1.14.19.17 | 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide |
i.e. ABC294640 |
|
| 1.14.19.17 | 4-((4-(4-chlorophenyl)thiazol-2-yl)amino)phenol |
i.e. SKI-II, noncompetitive inhibitor of enzyme Des1, structure-activity relationship analysis, inhibition mechanism, overview |
|
| 1.14.19.17 | 4-((5-(4-iodophenyl)-1,3,4-oxadiazol-2-yl)amino)phenol |
- |
|
| 1.14.19.17 | 4-oxo-N-(4-hydroxyphenyl)retinamide |
- |
|
| 1.14.19.17 | 4-oxo-N-(4-hydroxyphenyl)retinamide |
leads to an increase in C16 and C18 dihydroceramide substrate accumulation |
|
| 1.14.19.17 | 4-[[4-(4-chlorophenyl)-2-thiazolyl]amino]phenol |
i.e. dual sphingosine kinase 1-2 inhibitor SKI II, a noncompetitive inhibitor of Des1 activity, molecular modeling studies |
|
| 1.14.19.17 | 5-(4-chlorophenyl)-N-(4-hydroxyphenyl)-1,3,4-oxadiazol-2-amine |
- |
|
| 1.14.19.17 | alpha-cyclodextrin |
18% residual activity at a substrate/cyclodextrin molar ratio of 0.5 |
|
